Business UpdateMay 12, 2026, 04:02 PM
Molecular Partners advances lead Radio-DARPin MP0712; cash runway to late 2027
AI Summary
Molecular Partners AG announced significant progress across its clinical pipeline, with its lead Radio-DARPin MP0712 advancing in a Phase 1/2a trial and initial clinical data expected in 2026. The company also highlighted new data supporting its isotope-agnostic strategy for Radio-DARPins and progress in other programs like MP0317, MP0533, and MP0632. Molecular Partners reported a strong financial position with CHF 79 million (approx. USD 100 million) in cash, providing a runway until late 2027.
Key Highlights
- Lead Radio-DARPin MP0712 Phase 1/2a trial progressing with 4 sites open, 9 expected by year-end 2026.
- Initial clinical data for MP0712 expected in 2026.
- MP0317 Phase 2 study initiated with 8 sites activated, aiming to recruit 75 patients.
- MP0533 Phase 1/2a dose escalation fully recruited across 10 cohorts.
- Cash and short-term deposits totaled CHF 79 million (approx. USD 100 million) as of March 31, 2026.
- Financial runway extended until late 2027.
- New preclinical data for Switch-DARPin MP0632 presented at AACR 2026.
- Shareholders approved all Board motions at the AGM, including Clare Fisher's election to the Board.